October 17, 2024 11:12 AM EDT
News Briefing

Vi­a­tris, Lex­i­con ink li­cens­ing deal; Capri­cor’s $75M of­fer­ing

ENDPOINTS

Plus, news about Kezar Life Sci­ences and Con­cen­tra Bio­sciences:

Vi­a­tris, Lex­i­con Phar­ma­ceu­ti­cals sign li­cens­ing deal for car­dio drug: Per the agree­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Benev­o­len­tAI CEO is out af­ter less than a year on the job

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug

First clin­i­cal test of RNA edit­ing re­stores miss­ing pro­tein in ge­net­ic dis­ease, Wave says

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times